Divi's Labs' net profit jumps 17% to Rs 606 cr in Jul-Sept quarter
The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a filing to the BSE.

- Nov 6, 2021,
- Updated Nov 6, 2021 4:00 PM IST
Drug firm Divi's Laboratories on Saturday reported a 16.71 per cent jump in its consolidated net profit to Rs 606.46 crore for the quarter ended September 30, mainly on account of robust sales. The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a filing to the BSE.
Its consolidated total income during July-September 2021 stood at Rs 2,006.62 crore. It was Rs 1,762.94 crore in the year-ago period, it added.
The group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to the COVID 19 pandemic, Divi's Labs said.
Also Read: Department of Pharmaceuticals proposes to reduce time for regulatory approvals by 50%
Also Read: Sun Pharma's two US arms to pay $85 million in settlement pacts over antritrust litigation
Drug firm Divi's Laboratories on Saturday reported a 16.71 per cent jump in its consolidated net profit to Rs 606.46 crore for the quarter ended September 30, mainly on account of robust sales. The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a filing to the BSE.
Its consolidated total income during July-September 2021 stood at Rs 2,006.62 crore. It was Rs 1,762.94 crore in the year-ago period, it added.
The group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to the COVID 19 pandemic, Divi's Labs said.
Also Read: Department of Pharmaceuticals proposes to reduce time for regulatory approvals by 50%
Also Read: Sun Pharma's two US arms to pay $85 million in settlement pacts over antritrust litigation
